LOS ANGELES, Feb. 6 /PRNewswire-USNewswire/ -- Established in 2004, the Institute for Myeloma and Bone Cancer Research (IMBCR) is the only non-profit, independent cancer research institute focused on creating novel therapies and ultimately a cure for multiple myeloma and metastatic bone disease.
Ethan Horwitz, Esq. is a partner in New York law firm of King & Spalding and has an extensive Intellectual Property practice. Mr. Horwitz has over 25 years of experience in the full range of intellectual property law. For the past 30 years, Ethan has been an active board member and is a past president of Dorot. He also serves as a trustee of The Shalom Hartman Institute and of the Plaza Jewish Community Chapel.
Dr. James R. Berenson, medical and scientific director of IMBCR, comments on the addition of Horwitz: "Ethan will be a tremendous addition to our board of directors. He shares our passion and dedication to continue to offer cutting-edge research in the field of myeloma, bone disease and other blood cancers."
About IMBCR: The Institute for Myeloma and Bone Cancer Research is headquartered in Los Angeles, CA. IMBCR research is funded in part by donations from major foundations, including the Annenberg, Skirball, Lincy and Kramer Family Foundations, FJC, (A Foundation of Philanthropic Funds), Multiple Myeloma Research Foundation and Myeloma Research Fund. Collaborative research is also sponsored by major pharmaceutical companies. IMBCR research findings have been presented at annual meetings throughout the world. IMBCR research has been published in most major oncology journals. www.imbcr.org
|SOURCE Institute for Myeloma and Bone Cancer Research|
Copyright©2009 PR Newswire.
All rights reserved